2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 427

The Impact of Biologic Agent Initiation after 1 Versus 2 Prior Csdmards in Patients with Rheumatoid Arthritis
Abstract Number: 3238

The Impact of Biologic DMARD Treatment on Sepsis and Mortality after Serious Infection
Abstract Number: 34

The Impact of Cardiovascular and Lung Disorder Morbidities on Physical Activity in People with Inflammatory Arthritis Compared to the General Population in the UK
Abstract Number: 2480

The Impact of Emotional Trade-Off Difficulty on Choice
Abstract Number: 1614

The Impact of High Risk Susceptible Gene LILRA3 on Joint Inflammation in Rheumatoid Arthritis
Abstract Number: 1557

The Impact of Hindfoot Deformity on Disability of Korean Patients with Rheumatoid Arthritis
Abstract Number: 1345

The Impact of Prior Antibiotic Treatment on Culture Results of Patients with Septic Arthritis
Abstract Number: 2302

The Impact of Prior Fibromyalgia Treatment on the Response to Pregabalin in Fibromyalgia Clinical Trials
Abstract Number: 1566

The Impact of Severe Extra-Articular Manifestations and Patient Reported Outcome Measures on Cardiovascular Disease in Rheumatoid Arthritis
Abstract Number: 2939

The Impact of Tabalumab on the Kidney in Systemic Lupus Erythematosus: Results from Two Phase 3 Randomized Clinical Trials
Abstract Number: 592

The Impact of Tobacco Smoking on the Effectiveness of Abatacept in Rheumatoid Arthritis: Data from a Paneuropean Analysis of RA Registries
Abstract Number: 1418

The Importance of Comorbidity in Understanding the 6-Month Trajectories of Pain and Function after Total Hip Arthroplasty
Abstract Number: 3154

The Importance of Somatic Hypermutation for the Immunoreactivity Towards Neutrophil Extracellular Traps (NETs)-Citrullinated Autoantigens of RA Synovial Monoclonal Antibodies
Abstract Number: 1237

The Incidence and Prevalence of Systemic Lupus Erythematous in a Defined Population in United Arab Emirates
Abstract Number: 36

The Incidence of Cardiovascular Events in Patients with Rheumatoid Arthritis: a 15 Years Observational Cohort Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].